SLC25A18, another key marker, showed the highest expression levels in lower-grade gliomas (WHO grade II) with IDH mutation and in IDH-mutant, 1p19q co-deleted (LGG) subtypes. The gene discussed is SLC25A18; the disease is central nervous system cancer.